Holen Sie sich die Stockscreener-App
2.84
3.27%
0.09
Handel nachbörslich:
2.84
Schlusskurs vom Vortag:
$2.75
Offen:
$2.81
24-Stunden-Volumen:
25,887
Relative Volume:
0.69
Marktkapitalisierung:
$7.61M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-2.8119
EPS:
-1.01
Netto-Cashflow:
$-24.23M
1W Leistung:
+4.80%
1M Leistung:
+11.37%
6M Leistung:
-51.95%
1J Leistung:
-55.71%
1-Tages-Spanne:
$2.665
$2.84
1-Wochen-Bereich:
$2.36
$2.84
52-Wochen-Spanne:
$2.115
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
Firmenname
Moleculin Biotech Inc
Sektor
Branche
Telefon
713-300-5160
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten
Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com - Defense World
Moleculin Biotech Shares Rise 12% After Positive Annamycin Data - MarketWatch
Moleculin Biotech Sees Positive Data From Annamycin Study - MarketWatch
Moleculin Biotech’s Annamycin Shows Promise in Cancer Treatment - TipRanks
Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma - PR Newswire
Kendall Capital Management Buys 305 Shares of McKesson Co. (NYSE:MCK) - Defense World
Playstudios CFO sells $39,500 in stock By Investing.com - Investing.com Canada
Mitcham shares upgraded to outperform on value after preferred conversion - Investing.com India
Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Medipharm Labs Shares Jump on Clearing Remaining Debt - MarketWatch
MediPharm Labs Announces $2.1M Debt Repayment - Financial Times
Moleculin Biotech CEO Discusses Clinical Trials and Drug Development - TipRanks
Moleculin Biotech Shares Insights in Corporate Update - TipRanks
Moleculin Participates in Virtual Investor "What this Means" Segment – Company Announcement - Financial Times
Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated at StockNews.com - Defense World
Moleculin Biotech Advances Phase 2 Glioblastoma Study - TipRanks
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma - Marketscreener.com
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma - PR Newswire
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma - Yahoo Finance
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StreetInsider.com
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Moleculin to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Morningstar
Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - PR Newswire
Moleculin Biotech Raises Capital with Public Offering - TipRanks
Moleculin Announces Closing of up to $16.5 Million Public Offering - Financial Times
Q3 2024 EPS Estimates for Moleculin Biotech, Inc. (NASDAQ:MBRX) Cut by Analyst - Defense World
Moleculin Biotech (NASDAQ:MBRX) Stock Passes Below Fifty Day Moving Average of $3.45 - Defense World
Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com - Defense World
Moleculin Biotech Secures Funding for Drug Development Programs - TipRanks
Moleculin Prices of up to $16.5 Million Public Offering - citybiz
Moleculin sets terms for $5.5 million public offering - Investing.com
Moleculin sets terms for $5.5 million public offering By Investing.com - Investing.com UK
Moleculin Announces Pricing of up to $16.5 Million Public Offering - StockTitan
Moleculin to Present at the Virtual Investor Pitch Conference - Longview News-Journal
Moleculin Biotech gets Buy rating from Roth with strong trial results - Investing.com Australia
Moleculin Biotech gets Buy rating from Roth with strong trial results - Investing.com India
Moleculin Biotech gets Buy rating from Roth with strong trial results - Investing.com
Moleculin Biotech gets Buy rating from Roth with strong trial results - Investing.com UK
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Marketscreener.com
Moleculin Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
Moleculin Reports Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Moleculin Biotech (NASDAQ:MBRX) Share Price Passes Below Fifty Day Moving Average of $3.77 - Defense World
Moleculin Biotech Advances Phase 3 Trial for AML Treatment - TipRanks
Moleculin Biotech Advances to Phase 3 AML Trial - TipRanks
Moleculin to Host Webcast Presentation to Discuss Recently Announced Plans for MIRACLE Phase 3 Pivotal Trial Tuesday, August 6, 2024 at 8:30 AM ET - Longview News-Journal
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial - The Malaysian Reserve
Moleculin Biotech Unveils Corporate Strategy Update Presentation - TipRanks
Moleculin Biotech Advances to Phase 3 in AML Treatment Trial - TipRanks
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial - PR Newswire
Moleculin Biotech stock hits 52-week low at $3.21 - Investing.com
Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):